PALI · Palisade Bio, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on PALI. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About PALI · Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Live Quote
HOLD (score +3) · 12-1 mom 171.6% · RSI 54.4 · above_200_only · -30.7% from high
Targets blend Wall Street consensus (7 analysts: low $5.00 / mean $9.71 / high $25.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Four Form 4 filings clustered in June 2026 triggered this investigation, but upon reading the actual filing text, none represent open-market purchases. All four transactions (Wei Binxian, Donald Williams, Emil Chuang, Jordan Zwick) are RSU grants coded 'A' — equity compensation vesting as part of board appointments and annual awards. The February cluster similarly reflects RSU settlement activity for employees (Mitchell Jones/CMO and JD Finley/CEO/CFO), with code S sales only covering tax withholdings on vested shares, not directional bets. No genuine open-market insider purchase has occurred in the past 90 days. PALI is a pre-revenue micro-cap biotech ($297M market cap) with $133M cash burning ~$10M/quarter in R&D; it has no products approved and its sole lead asset (PALI-2108) just completed Phase 1b. A Phase 2 UC trial starting Q3 2026 is the primary near-term catalyst. The stock trades at $1.71, well off its 52-week high of $2.86; technicals are bearish with MACD below signal and RSI in neutral territory at ~40.